A novel treatment for cannabis dependence?
PI: Professor Val Curran & Dr. Celia Morgan
Research Associates: Dr Tom Freeman & Chandni Hindocha
Collaborator: Dr. Paul Morrison, IoP
£1.3million Medical Research Council
More people are dependent on cannabis than any other illicit drug – at least 18 million worldwide. In Europe, 1% of all adults and nearly 2% of 14-17 year olds are addicted to cannabis. Rates of cannabis dependence have increased markedly over recent years alongside changes in the ingredients of cannabis available on the. Among UK first-time drug treatment clients, cannabis is now the primary addiction in 28% of those entering drug treatment, second only to heroin (41%).
The demand for cannabis treatment has more than doubled since 2001 (UNODC World Drug Report 2010). At present, clinicians rely on psychological treatments which have very limited effectiveness. If we found a safe, effective medicine this could improve treatment in a similar way that various medicines have improved rates of stopping tobacco use. It would also impact on educational/vocational achievement and illegal behaviour, and reduce young people’s risks of cannabis-associated mental health problems (e.g. schizophrenia, depression).
This project will first determine which dose of a novel pharmacological treatment is best in treating cannabis dependence before fully evaluating its efficacy.
We are inviting participants to take part who are at least 16 years old, meet clinical criteria for cannabis dependence and would like to stop using the drug.